What Unimax does

Unimax is a privately held Indian pharmaceutical manufacturer operating through two core subsidiaries: Unimax Chemicals Pvt Ltd (UCPL), focused on macrolide antibiotic APIs including erythromycin salts, azithromycin variants, clarithromycin, and roxithromycin along with related intermediates; and Unimax Laboratories Pvt Ltd (ULPL), a dedicated facility for glucocorticosteroid APIs including dexamethasone and betamethasone compounds. Founded in 1985 (originally as Nirav Fine Chemicals) with the current entity established in 1990, the company operates three cGMP-compliant manufacturing facilities in Tarapur, India with combined annual production capacity of 300 metric tons, including a newly inaugurated EUGMP and USFDA-compliant block in 2023. The company's technology base spans complex organic chemistry (chiral chemistry, Beckmann's re-arrangement, Grignard reactions, Friedel-Crafts), green chemistry process development, and ISO 8 clean-room finishing capabilities for crystallization, drying, milling, blending, and micronization.

Unimax generates revenue through three streams: (1) sale of generic APIs and intermediates to API/formulation manufacturers globally (described as a one-time license/transactional model), (2) supply of macrolide intermediates (Erythromycin Oxime Base, Imino Ether) to API manufacturers, and (3) custom synthesis and contract manufacturing services for global pharmaceutical innovators and Big Pharma companies. Its go-to-market is direct B2B enterprise sales complemented by event-driven lead generation at industry exhibitions such as CPHI Barcelona 2023. Pricing is custom-quoted based on product specifications, volume, regulatory documentation, and destination-country registration requirements. The company holds WHO GMP, EU Written Confirmation, CEP Registration Number 2023-189 for Erythromycin Base, and FDA Maharashtra/DGDA certifications, serving customers in over 50 countries across Asia, Europe, Middle East, Asia Pacific, and Latin America. Leadership is family-controlled, with 100+ employees across the group and a development pipeline expanding into antiepileptics, antiplatelets, NSAIDs, and antidiabetics beyond the historical antibiotic/corticosteroid core.

Name

Unimax

Legal name

Unimax Chemicals Pvt Ltd

Website

https://unimax.co.in

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Miscellaneous Chemical Products (2890)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Pharmaceutical API manufacturing
• Generic active pharmaceutical ingredients
• Macrolide antibiotic APIs
• Glucocorticoid steroid APIs
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Generic API Sales: Sale of manufactured generic Active Pharmaceutical Ingredients including Erythromycin-based antibiotics, Azithromycin, Clarithromycin, and Glucocorticosteroids to API and formulation companies globally
2. Pharmaceutical Intermediates: Supply of pharmaceutical intermediates including Erythromycin Oxime Base, Imino Ether, and other macrolide intermediates to API manufacturers
3. Contract Manufacturing Services: Custom synthesis and contract manufacturing services for global innovator companies and pharmaceutical majors. Development and optimization of processes for APIs and intermediates

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Core offering

Unimax is a research-driven Indian pharmaceutical manufacturer that produces and globally supplies generic Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates — specializing in macrolide antibiotics (Erythromycin, Azithromycin, Clarithromycin, Roxithromycin) and glucocorticoid steroids (Dexamethasone, Betamethasone, Prednisolone, Mometasone) — and offers custom synthesis and contract manufacturing services to global innovator and Big Pharma companies from three cGMP-compliant manufacturing facilities with a combined 300MT annual capacity.

Product overview

Unimax is a pharmaceutical company operating through two main business units: UCPL (Unimax Chemicals Pvt Ltd) and ULPL (Unimax Laboratories Pvt Ltd). UCPL specializes in macrolide antibiotic APIs including erythromycin-based products, azithromycin variants, clarithromycin, and roxithromycin, along with related intermediates for these antibiotics. ULPL operates as a dedicated glucocorticoid corticosteroid manufacturing facility producing APIs like dexamethasone, betamethasone, and related steroid compounds. The company also offers contract manufacturing services for global pharmaceutical innovators. Unimax provides over 26 generic API products globally and develops new molecules across therapeutic categories including antifungals, antivirals, antihypertensives, antidiabetics, and NSAIDs. Products are available in multiple pharmacopoeia standards (IP/BP/EP/USP/JP) with WHO GMP and EU Written Confirmation certifications.

Differentiator

Problem solved

Functional benefit

Brands

• UCPL: Product division offering APIs, intermediates, and products under development including Erythromycin-based products, Azithromycin, Clarithromycin, and others
• ULPL

Products and services

• Generic Active Pharmaceutical Ingredients (APIs) Over 26 generic Active Pharmaceutical Ingredients manufactured and supplied globally, comprising macrolide antibiotics (Erythromycin Base and salts such as Stearate, Estolate, Ethyl Succinate, Propionate, Phosphate, Lactobionate, 11-12 cyclic carbonate; Azithromycin Dihydrate, Anhydrous/Base, Monohydrate, taste-masked powder, premix for suspension; Clarithromycin Powder; Roxithromycin) and glucocorticoid corticosteroids (Dexamethasone Sodium Phosphate, Betamethasone Sodium Phosphate, Prednisolone Sodium Phosphate, Mometasone Furoate, Betamethasone Dipropionate, Beclomethasone Dipropionate, Betamethasone 17 Valerate, Clobetasole 17 Propionate, Triamcinolone Acetonide, Diflucortolone Valerate). Available in IP/BP/EP/USP/JP pharmacopoeia standards with WHO-GMP and EU Written Confirmation certifications. Targeted at global API manufacturers, formulation companies, big pharma, and multinational companies.
• Pharmaceutical Intermediates Pharmaceutical intermediates supplied from a WHO-GMP approved plant, including macrolide intermediates such as Erythromycin Oxime Base, Imino Ether, Des Azithromycin/Aza Amine, 6-O-Methyl-2',4''-bis-O-(trimethylsilyl)erythromycin 9-[O-(1-ethoxy-1-methylethyl)oxime], and Silylated Erythromycin Oxime Ketal, used in the production of Azithromycin and Clarithromycin. Targeted at API manufacturing companies seeking quality intermediates and backward-integration support.
• Contract Manufacturing Services Custom synthesis and contract manufacturing services for APIs and intermediates provided to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions, development and optimization of processes for APIs and intermediates, and development of non-infringing processes for strategic patent-constrained products. Targeted at global innovator companies and pharmaceutical majors needing a cGMP-compliant manufacturing partner with flexible capacity from gram-scale to MT.

Quantifiable outcome

• Over 26 generic API products offered globally
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Global Pharmaceutical InnovatorscoreStrategic or Co-development PartnerUnimax provides contract manufacturing services for APIs and intermediates to global pharmaceutical innovators and big pharma companies. Capabilities include handling high energetic reactions and developing optimized non-infringing processes for strategic partnership collaborations.

Scale indicators8 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• Teva API: Global generic API division of Teva Pharmaceutical, one of the world's largest producers of steroid and macrolide APIs. A broader incumbent competing with Unimax across multiple product categories and regulated geographies.
• Divi's Laboratories: One of India's largest API manufacturers with a broad generic API and custom synthesis portfolio. Comparable to Unimax in offering complex chemistry contract manufacturing and serving Big Pharma customers, but at significantly greater scale.
• Sandoz (Novartis): Global leader in generic APIs and finished dosages with vertical integration into API manufacturing. Competes with Unimax as a buyer-side anchor customer in some products and a competing supplier in others, particularly in antibiotics and corticosteroids.
• Aurobindo Pharma: Large vertically integrated Indian generic API and finished dosage manufacturer with a broad macrolide and steroid portfolio. A relevant peer because it competes head-to-head with Unimax in the same generic API categories while also operating formulation businesses that pull through API demand.

Direct peers

• Ipca Laboratories: Indian API and formulation manufacturer with direct overlap in macrolide antibiotics and corticosteroids. Highly comparable to Unimax in scale, product mix (API + intermediates + formulations), and customer base of generic formulation companies.
• Hikal Limited: Indian API and intermediates manufacturer serving pharma and agrochemical customers with active presence in macrolide intermediates. Directly comparable to Unimax's UCPL business in intermediates supply and custom synthesis capabilities.
• Centrient Pharmaceuticals: Dutch-headquartered global leader in generic beta-lactam and macrolide antibiotic APIs. Highly comparable to Unimax because it competes directly in Erythromycin, Azithromycin, and Clarithromycin APIs and serves the same global formulation customer base.
• Dishman Carbogen Amcis: Indian-headquartered contract API manufacturer with global CRAMS operations. Comparable to Unimax because it competes in contract manufacturing and custom synthesis for innovator pharma, with overlapping complex chemistry capabilities.
• Granules India: Indian API and finished dosage manufacturer with a portfolio that includes select antibiotics and is expanding into corticosteroids. Comparable to Unimax as a mid-sized Indian API player targeting global formulation customers with backward-integrated manufacturing.
• SMS Pharmaceuticals: Indian API manufacturer focused on steroids, hormones, and complex generics. A close peer to Unimax's ULPL business unit because both compete in corticosteroid APIs (Dexamethasone, Betamethasone, Prednisolone) for global formulation customers.

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unimax